NanoViricides to Test Oral Ebola Drug in the Democratic Republic of Congo

Kinshasa, Tuesday, 15 September 2026.
Next week, NanoViricides will launch Phase II trials for an oral Ebola treatment in the Democratic Republic of Congo, targeting a severe outbreak with a 48% fatality rate.